HER2-EGFR Combination Therapy for Resistant Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors expressing EGFR and HER2 often show limited efficacy when used as single agents, and there is a need for effective therapies that can target tumors refractory to chemotherapy and radiation therapy, particularly those with HER2 receptor overexpression or amplification.
Innovation Solution
Administering a combination of a HER2-dimerization inhibitor and an EGFR inhibitor, such as pertuzumab and erlotinib, to patients with tumors that have shown partial or no response to these agents alone, including those with HER3 expression and those refractory to chemotherapy or radiation, to achieve synergistic anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a HER2-dimerization inhibitor or EGFR inhibitor is administered as a single agent, then the treatment is simpler and easier to administer, but the anti-tumor efficacy is limited and the tumor shows resistance
Solution Approach 1:
The patent combines HER2-dimerization inhibitors (such as pertuzumab) and EGFR inhibitors (such as erlotinib or gefitinib) into a combination therapy regimen. This merging of two different therapeutic agents targets multiple pathways simultaneously - blocking HER2 heterodimerization and inhibiting EGFR tyrosine kinase activity - thereby overcoming the limited efficacy of single-agent treatments while maintaining manageable administration protocols
2Reliability
If combination therapy with HER2-dimerization inhibitor and EGFR inhibitor is administered, then the anti-tumor efficacy is enhanced, but the treatment complexity increases
Solution Approach 1:
The combination therapy is segmented into distinct functional components with clear mechanisms of action: the HER2-dimerization inhibitor specifically blocks HER2 heterodimer formation at the cell surface, while the EGFR inhibitor specifically blocks EGFR tyrosine kinase activity intracellularly. This segmentation of therapeutic functions allows for targeted intervention at multiple points in the signaling pathway, enhancing efficacy while maintaining clarity in treatment design and monitoring
3Loss of time
If single-agent therapy is used, then the treatment cost and administration burden are lower, but the tumor progression time is shorter and survival outcomes are poorer
Solution Approach 1:
The combination therapy introduces intermediary mechanisms that block tumor progression through multiple pathways. The HER2-dimerization inhibitor acts as an intermediary that prevents HER2 receptor activation, while the EGFR inhibitor serves as another intermediary that blocks downstream signaling. These intermediary actions work synergistically to delay disease progression and improve survival outcomes beyond what either agent could achieve alone
Data Source
AI summary
The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.